Mr. Finney currently serves as President and Chief Executive Officer of Autobahn Therapeutics and Chairman of its Board of Directors since 2019.
Prior to joining Autobahn, Mr. Finney served as President, Chief Operating Officer, and a Director of Abide Therapeutics through the company’s acquisition by Lundbeck in 2019. Prior to this, Mr. Finney founded and served as the Chief Operating Officer of Zavante Therapeutics through the company’s acquisition by Nabriva Therapeutics in 2018. Mr. Finney previously spent a decade as Head of World-Wide Corporate Development at Allergan, Inc.
Prior to Allergan, Mr. Finney held executive management roles at Prometheus Laboratories, Inc. (now Nestle Health Science), Amylin Pharmaceuticals, Inc. (now Bristol-Myers Squibb), and the Parke-Davis division of Warner-Lambert (now Pfizer). In addition to his role at Autobahn, Mr. Finney serves on the board of Eirion Therapeutics and previously served on the boards of Elsie Biotechnologies (now GSK), Taris Biomedical (now J&J), and Anterios (now Allergan).
Mr. Finney holds an MBA from the George L. Graziado School of Business, Pepperdine University, and a B.A. in Exercise Physiology from California State University Long Beach.
